MedTrace Logo

Chiauranib in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma

NCT06492915 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2026-03-18

No results posted yet for this study

Summary

Chiauranib , which simultaneously targets against VEGFR/Aurora B/CSF-1R, several key kinases involved in tumor angiogenesis, tumor cell mitosis, and chronic inflammatory microenvironment.

Conditions

Interventions

DRUG

Chiauranib

Chiauranib, 25 mg, 35 mg or 50 mg, oral administration once daily

DRUG

Albumin-paclitaxel Injection

Albumin-paclitaxel Injection, 125 mg/m\^2 administered intravenously on Days 1, 8 and 15 of each 28-day cycle

DRUG

Gemcitabine Injection

Gemcitabine Injection, 1000 mg/m\^2 administered intravenously on Days 1, 8 and 15 of each 28-day cycle

Sponsors & Collaborators

  • Chipscreen Biosciences, Ltd.

    lead INDUSTRY

Principal Investigators

  • Xianjun Yu · Fudan University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-08-13
Primary Completion
2026-05-31
Completion
2026-10-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06492915 on ClinicalTrials.gov